Visa has topped a buy point, while fellow S&P 500 component Insulet gapped out of a base, leading five stocks on this weekend watchlist.

Learn more about whether BioCryst Pharmaceuticals, Inc. or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take ...

Halozyme Therapeutics HALO has outperformed the market over the past 15 years by 4.64% on an annualized basis producing an ...

Here is our list of the 10 best cancer stocks to invest in for long term gains. Summit Therapeutics Inc. (NASDAQ:SMMT) is a ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...

Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025. Shares rise.

Q1 2025 Management View CEO Helen Torley emphasized the company’s focus on both organic and inorganic growth, with a strategy ...

Halozyme Therapeutics, Inc. ( NASDAQ: HALO) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Tram Bui - Vice President, Investor Relations & Corporate Communications Helen Torley - President & ...

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 16.84% and 10.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO (AP) — SAN DIEGO (AP) — Halozyme Therapeutics Inc. (HALO) on Tuesday reported first-quarter profit of $118.1 million. On a per-share basis, the San Diego-based company said it had profit of ...

Halozyme Therapeutics, Inc. ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the BofA Securities 2025 Healthcare ...